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Robert Edwards was awarded the 2010 Nobel Prize in Physiology or Medicine for the development of human
in vitro fertilization. His work not only provided the means to overcome many forms of infertility, but it also
enabled research on early stages of human embryos and the derivation of human embryonic stem cells.It was with great excitement that investi-
gators and clinicians in the field of re-
production received the news that the
2010 Nobel Prize in Physiology or Medi-
cine was awarded to Professor Robert
G. Edwards for his contributions to the
development of human in vitro fertilization
(IVF). With the exception of transfusion
medicine, human IVF and embryo transfer
represents the only other medical inter-
vention that involves the removal of cells
from the body, processing of these cells
in the laboratory, and the eventual re-
introduction of the ‘‘processed’’ cells re-
sulting in a successful therapy of
a medical condition. Infertility, which is
defined as the inability to conceive after
1 year of unprotected intercourse, affects
approximately one in seven couples of
reproductive age in the United States. It
is a major medical and social problem,
and it was not until the development of
clinical human IVF that many diverse
causes of infertility could be successfully
overcome. With the exception of infertility
secondary to anovulation, which was
easily ‘‘cured’’ once ovulation induction
hormonal regimens were developed, no
other fertility treatment has met with the
success of IVF. It is estimated that 2%–
3% of all births in developed countries
are the result of IVF procedures. In addi-
tion, there are strong prospects for
applying this treatment in a cost-effective
way to wider infertility populations. The
births made possible by IVF, now and in
the future, are clear tangible results of
this important basic research. However,
the development of IVF has another
significant impact as well. Edwards’ No-
bel Prize-winning work has also enabled
research that could improve the quality
of life for millions more by providing the12 Cell Stem Cell 8, January 7, 2011 ª2011 Ebasis for deriving human embryonic
stem cells (hESCs), which may be used
to restore tissues lost or damaged
because of disease or injury.
The history of both the research and the
clinical application leading to human IVF
is very instructive, and clear parallels can
be drawn with the modern, growing field
of hESC research. Here, we offer an
abbreviated historical perspective of the
development of human IVF and discuss
how some of the lessons learned might
help inform the current debate over poli-
cies regulating hESC research.
The Path to the Birth of the First IVF
Babies
The very first in vitromanipulation of eggs/
embryos was performed byWalter Heape
(1890), when he transferred in vivo fertil-
ized eggs from one female rabbit to
another and achieved pregnancy and
subsequent delivery of Angora rabbits
similar to the biological parents’ breed. It
is interesting that successful embryo
transfers in other species did not happen
until much later, with rat, sheep, goat,
and mouse pregnancies reported in the
1930s, and eventually cow and pig
embryo transfers in the 1950s (for histor-
ical reviews, see Biggers, 1981; Wolf
and Quigley, 1984). These experiments
all involved in vivo conceptions and
subsequent transfer of the resulting
embryos to a pseudopregnant recipient,
usually of a different breed.
Attempts at IVF also date back to the
late 1800s. Specifically, Schenk attemp-
ted to fertilize rabbit and guinea pig
oocytes in vitro; however, there was no
unequivocal proof that sperm had entered
the eggs. It was not until 1959 when M.C.
Chang, using rabbits, provided unequiv-lsevier Inc.ocal proof of successful IVF (Chang,
1959).
Parallel laboratory work refined the
culture techniques for mammalian em-
bryo development in vitro. While the
development of these methods aided
the eventual establishment of clinically
relevant IVF, it could be argued that the
more significant contribution of these
efforts was to uncover molecular mecha-
nisms behind the physiology and cell
biology of oocyte maturation and early
embryo development. Even though
many individuals may have considered
proceeding with human IVF during this
period, it was Robert Edwards who first
put these thoughts into action and
achieved IVF of human eggs that were
obtained from excised ovaries and
matured in vitro prior to fertilization (Ed-
wards et al., 1969). The fertilization effi-
ciency using this approach was extremely
low, largely due to the complexities of
in vitro maturation of the developmentally
arrested oocytes. The subsequent break-
through of retrieving human eggs that
were first matured in vivo and shown to
achieve efficient fertilization and early
development in vitro (Edwards et al.,
1970) was quickly translated into clinical
practice. Despite this promising finding,
when additional attempts were made by
Edwards and his clinical collaborator,
Patrick Steptoe, to obtain multiple mature
human eggs following treatment of
women with ovulation-inducing agents,
pregnancies were not achieved and so
they abandoned this approach.
Finally, in 1977, a mature egg obtained
during a natural cycle was fertilized
in vitro and transferred back to the egg
donor, resulting in the first pregnancy
and the birth of Louise Brown in July of
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Almost concurrently, the Australian team
of Lopata and colleagues also succeeded
using the natural ovulatory cycle, and then
Trounson and theMonash group reported
the use of fertility drugs, ovulatory control-
ling strategies, and delayed insemination
that substantially increased embryo
production and pregnancy success rates
for IVF (see Cohen et al., 2005 for specific
references and amore complete historical
accounting). These major breakthroughs
were then quickly transferred to the UK,
France, Belgium, and the United States.
IVF and the associated technologies
developed with and around it are now
collectively referred to as ‘‘assisted repro-
ductive technologies,’’ or ART.
Technical Developments Continue
During the decade following the first IVF
births, progress continued with three
major technical advances that contrib-
uted to innovative treatments and to our
understanding of basic molecular and
cellular processes involved in fertilization
and early development in the human.
The first such advance, establishing
safe cryopreservation techniques, came
in response to the collection of multiple
eggs and embryos (see Cohen et al.,
2005). This method enabled the storage
of excess embryos for the patient’s future
use, thus avoiding further ovarian stimula-
tion and allowing clinicians to restrict the
number of embryos transferred to the
patient on any one occasion in order to
limit high-order multiple births. Cryopres-
ervation techniques made it possible for
couples who did not desire additional
children to donate stored embryos to
other infertile couples or to research. Indi-
rectly, therefore, the combination of IVF
and embryo cryopreservation made the
generation of human embryonic stem
cells possible.
The second advance was the develop-
ment of intracytoplasmic sperm injection
(ICSI), which showed that the injection of
a single sperm into a human oocyte was
sufficient to achieve fertilization, preg-
nancy, and live birth (see Cohen et al.,
2005). This technique not only offered an
alternative to male factor infertility, which
affects approximately one-third of infertile
couples, but also provided clues to under-
standing functional aspects of sperm
physiology and elements of egg activation
and early development.The third technical advance in the field
was the introduction of blastomere
biopsy, which allowed for the diagnosis
of genetic diseases at the level of the pre-
implantation embryo and also provided
the opportunity to uncover molecular
mechanisms regulating early embryonic
cell differentiation (Handyside et al.,
1990). Clearly, this technology provided
at least the technical means that subse-
quently allowed the development of ap-
proaches to generate human embryonic
stem cells from single blastomeres
without destroying the embryo.
Clinical IVF, hESCs, Science,
and Society
This brief historical overview clearly de-
monstrates the importance of the devel-
opment of IVF to the birth of the field of
hESC biology. The availability of spare
human embryos generated via IVF,
made available by choice and consent of
the parents, opened the door for their
use in research. As such, the develop-
ment of human IVF and its associated
laboratory methodologies, culture tech-
niques, and other technical aspects
played a critical role in enabling hESC
research and its potential future clinical
applications.
As is observed for many great innova-
tions that impact society, IVF raised its
share of ethical, moral, religious, and
political issues. Among these concerns
were that any children born would not be
normal, that society was poised on a slip-
pery slope that carried the risk of playing
God or would lead to eugenics, baby
farms, human cloning, an explosion in
the world’s population, and so on.
Edwards was also faced with criticism
from some prominent scientists and the
continued need for research funding. For
example, the MRC rejected his applica-
tion to fund his IVF studies (see Johnson
et al., 2010 for a more detailed account).
Yet, with the successful clinical demon-
stration that IVF could overcome infertility
in many patients, the technique became
accepted, widely practiced, and the loud
criticisms diminished. Edwards engaged
the public with his advocacy of IVF and
strongly promoted oversight and regula-
tion of this field (Edwards, 1974), which,
in the UK, eventually resulted in the
passage of the Human Fertilisation and
Embryology Act in 1990. This act
provided oversight and regulation notCell Stem Celonly of IVF but also for human embryo
research. Edwards’s experiences have
provided lessons for those pursuing other
promising yet controversial medical
advances, none more so than the work
IVF has directly enabled: the derivation
of hESCs.
In the 1990s, several laboratories were
pursuing the derivation of hESCs using
procedures that resulted in embryo
destruction. These efforts were under-
taken because investigators recognized
the potential importance of hESCs in
basic research and ultimately as a source
of cells for therapies, as Edwards had
foreseen and promoted (Edwards, 1982).
Indeed, it could be argued that Edwards
himself was the intellectual founder of
hESC research. With the first publication
of hESC derivation in 1998 came a
pronounced vocal opposition that echoed
the objections Edwards experienced in
response to human IVF. In contrast,
however, the hESC debate, which con-
tinues to this day, has been largely
focused on the destruction of embryos
(e.g., that an embryo is a human being
or a nascent human being). Given that
typical IVF practices give rise to embryos
that are not used for reproduction, this
technique has always been faced with
the contentious issue of the frequent dis-
carding of human embryos. However,
this point had not been widely debated
until after the derivation of hESCs brought
the practice more visibly into the public
domain. Lewis Wolpert (Wolpert, 2001),
and others, have pointed out repeatedly
that there is no ethical difference between
IVF and deriving hESCs in that both prac-
tices require the creation and destruction
of embryos. With IVF, a significant
number of embryos are discarded either
because they do not meet the criteria for
uterine transfer or because patients have
completed their treatments and no longer
have need for their cryopreserved em-
bryos. Although the embryos were pro-
duced with the intent of reproduction,
patients have been given the opportunity
to provide the embryos for research,
including for hESC derivation. IVF is per-
formed regularly in countries where
hESC research (or the derivation of
hESC lines) is banned. One could ques-
tion whether it is rational to support clin-
ical IVF and yet oppose ESC derivation.
(For the legal status of hESC research in
countries and in U.S. states, check thel 8, January 7, 2011 ª2011 Elsevier Inc. 13
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regions).
It is important to acknowledge the
invaluable contributions that infertile cou-
ples, particularly the women subjected to
medical treatments, failures, and surgical
procedures in the hope of achieving a
pregnancy, have made to the develop-
ment of clinical human IVF. In a sense,
they should share, in spirit, the Nobel
prize with Robert Edwards. Furthermore,
couples that have provided embryos for
research purposes are largely unsung
heroes who have enabled the develop-
ment of the hESC field which, it could be
argued, holds an even greater promise
than clinical IVF in terms of potential




The pace of stem cell research and inno-
vation and the utilization of the knowledge
gained from the study of ESCs will
continue to change the strategies em-
ployed for developing clinical therapies.
At present, there is still a need for
research with hESCs and some of the
newer developments, such as induced
pluripotency, which is assumed widely
to replace hESCs, are not without their
own ethical and moral issues. In the
U.S., remarkable progress has been
made despite numerous political obsta-
cles, thanks mainly to dedicated investi-
gators and funding from philanthropic
donors, supportive states, and disease-
and patient-based organizations. The
FDA has now approved two clinical trials
that will transplant hESC-derived cells:
oligodendrocyte progenitors for spinal
cord injury and retinal pigmented ep-
ithelial cells for Stargardt’s macular
dystrophy. Should these and other
upcoming trials prove successful, it
seems likely that support for the clinical
utility of hESCs will follow. Indeed, if the
parallels with IVF’s journey into main-
stream clinical practice continue, a thera-
peutic success for hESCs may well
overshadow any lingering objections to
ongoing basic research efforts and tech-
nological development that remain essen-
tial to the growth of this field.
For the past 40 years, the U.S. govern-
ment has not followed through on recom-
mendations of committees that have been
empanelled to propose scientifically14 Cell Stem Cell 8, January 7, 2011 ª2011 Esound, ethical, and regulated policies,
including funding, on human embryo
research. This lack of progress has led
to the development of hESC research
guidelines by the National Academy of
Sciences/National Research Council and
the International Society for Stem Cell
Research for voluntary adherence. The
NIH policy, more limited than the non-
public organizations on what research is
eligible to receive funding, has evolved
over time as well. For ART in the U.S.,
there are voluntary guidelines that have
been developed by the American Society
for Reproductive Medicine, the clinical
field’s professional society.
In our opinion, the lack of a rational,
widely acceptable policy on the use of
human embryos in research has compro-
mised hESC research in the U.S. Unlike
IVF, whose wide acceptance came on
the heels of a relatively rapid and highly
visible demonstration of clinical success,
hESC research will take years to ‘‘trans-
late’’ into routine clinical use. Opponents
of hESC research are quick to point out
that no one has been cured using hESCs
even 12 years after their derivation.
Recent years have seen an escalation of
much needed federal funding for hESC
research, but this support is now jeopar-
dized by a legal challenge on the use of
federal funds for human embryo
research. The lawsuit before the U.S.
District Court in Washington D.C. illus-
trates the vulnerability of current policy
reflecting differences of opinions on the
interpretation of a law. If patients are to
benefit from the impressive progress
made in ESC research over the past
decade, it is clear that federal funding
and legislative action are both required.
Congress must define what is eligible
for federal funding, address the current
law and provide for authorization of
expenditures of funds for human embryo
research. Either the NIH (or a public body
established for this purpose) could
resolve the complex issues surrounding
the use of embryos in research. Only
with transparent public deliberations
among scientific experts, social scien-
tists, and legislators can much needed
guidance emerge. This will not be easy
to achieve, given the existing perceptions
of ‘‘medical naivete´’’ and political consid-
erations and pressures. Nevertheless, it
is imperative to achieve an outcome
that would permit and support the fund-lsevier Inc.ing of sound science involving a legitimate
use of human embryos in research,
particularly the use of existing embryos
that couples have no further plans to
use and do not wish to donate to other
infertile couples. The legislative process
may prove difficult politically but each of
us must realize our responsibility to
pursue every opportunity to alleviate the
suffering and to improve the quality of
life for those citizens in desperate need
of therapies. It is not surprising that in
our pluralistic society there are wide
differences of opinions on the moral and
ethical values of the earliest stages of
human development. We must accept
that there are compelling views and
sound science for a legitimate use of
embryos in research that could improve
the quality of life for many, as well as
save lives. It is accurate to say that
a majority of Americans have come to
a consensus that we should pursue
hESC research with proper guidelines,
oversight, and government funding.
Legislation should reflect this consensus.
Human IVF, despite initial resistance by
society and, indeed, from within the
medical community, has proven to be
a key treatment of infertility. This practice
is now firmly established in clinical medi-
cine, although additional improvements
continue to be needed and sought.
Although Robert Edwards was awarded
the Nobel Prize for his scientific con-
tributions in the development of IVF tech-
nologies, his vision extended beyond
treatments for infertility, and included
embryonic stem cells. As a society, we
must now manage this newer offspring
of IVF with policies that will enable the
pursuit of human embryo research that
will serve to benefit all people.REFERENCES
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